In the Viewpoint entitled “Drugs for Macular Degeneration, Price Discrimination, and Medicare’s Responsibility Not to Overpay” published in the July 2, 2014, issue of JAMA (2014;312:23-24. doi:10.1001/jama.2014.6672), the description of ranibizumab as the Fab portion of bevacizumab in the second paragraph was not accurate. The sentence should have read: “After bevacizumab was introduced, the manufacturer, Genentech, received approval from the US Food and Drug Administration (FDA) for a genetically engineered variant of the Fab portion of bevacizumab to be used in small doses intraocularly to treat neovascular AMD.” The article was corrected online.
Drug Derivation Clarified. JAMA. 2014;312(19):2045. doi:10.1001/jama.2014.14363